Incomplete success of angioinhibitor therapy in cancer: Estimation of contribution of pro-angiogenic activity of patient thyroid hormone

Paul J. Davis, Murat Yalcin, Hung Yun Lin, Heng Yuan Tang, Aleck Hercbergs, John T. Leith, Faith B. Davis, Mary K. Luidens, Shaker A. Mousa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content-including thyroid hormone-in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.

Original languageEnglish
Pages (from-to)441-445
Number of pages5
JournalJournal of Cancer Science and Therapy
Volume5
Issue number12
DOIs
Publication statusPublished - 2013

Keywords

  • Angiogenesis
  • Chick chorioallantoic membrane (CAM) assay
  • Integrin αvβ3
  • Thyroxine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Incomplete success of angioinhibitor therapy in cancer: Estimation of contribution of pro-angiogenic activity of patient thyroid hormone'. Together they form a unique fingerprint.

  • Cite this